HK Stock Market Move | CANSINOBIO (06185) morning trading up nearly 10%, revenue from meningococcal vaccine continues to grow, annual net profit turns from loss to profit.

CANSINOBIO (06185) rose by nearly 10% in the morning, rising 9.49% to 34.16 Hong Kong dollars as of the time of publication, with a turnover of 2834.76 million Hong Kong dollars. In terms of news, CANSINOBIO released its annual performance report. The company achieved annual operating income of 1.059 billion RMB, an increase of 28.43% year-on-year; the company's attributable profit to owners was 27.873 million RMB, turning loss into profit year-on-year. In addition, the company announced a three-year shareholder dividend return plan, emphasizing the principle of cash dividends first. The announcement stated that the growth in performance during the reporting period was mainly due to the continuous growth in revenue of the company's core product, China's first quadrivalent meningococcal vaccine, Manhixin. The company has continued to implement a development strategy with innovation at its core and commercialization as its focus, deepening cost reduction and efficiency enhancement, optimizing production and sales coordination, and continuously improving operating efficiency.